Skip to content

Study · In vitro (cells) · 2008

3 results

The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data.

Lo Nigro C, Maffi M, Fischel JL, Formento P, Milano G, Merlano M

BJU international20 May 2008Cited by 31 (Europe PMC)

PMID18494832 (opens in a new tab)DOI10.1111/j.1464-410x.2008.07706.x (opens in a new tab)PepBankPUB-18494832
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In prostate cancer cells, adding lanreotide to docetaxel inhibited growth more than docetaxel alone, particularly in resistant cells.

    In plain wordsIn cells, adding lanreotide reduced growth more than docetaxel alone, especially in resistant prostate cancer cells.

    Peptide
    Lanreotide
    Outcome
    DecreaseCell growth
    Study

    humann: not reported in source

    PC3 and docetaxel-resistant PC3R prostate cancer cells
    Comparator
    Docetaxel alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Combined treatment with docetaxel and lanreotide inhibited PC3 cell growth in vitro through an enhanced induction of cell death, compared with treatment with either agent alone; this result was particularly evident on PC3R cells.
    1 context sentence
    Summary · context
    To evaluate the effects of the association between docetaxel and the somatostatin analogue lanreotide on the androgen-independent prostate cancer cell line PC3, either sensitive or made resistant to docetaxel (PC3R), as new drugs and new combinations have promising clinical activity in hormone-refra…
  2. 02LabIn vitro (cells)Efficacy outcome

    In prostate cancer cells, adding lanreotide to docetaxel enhanced cell death compared with docetaxel alone.

    In plain wordsIn cells, adding lanreotide increased prostate cancer cell death compared with docetaxel alone.

    Peptide
    Lanreotide
    Outcome
    IncreaseCell death
    Study

    humann: not reported in source

    PC3 and docetaxel-resistant PC3R prostate cancer cells
    Comparator
    Docetaxel alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Combined treatment with docetaxel and lanreotide inhibited PC3 cell growth in vitro through an enhanced induction of cell death, compared with treatment with either agent alone; this result was particularly evident on PC3R cells.
    1 context sentence
    Summary · context
    To evaluate the effects of the association between docetaxel and the somatostatin analogue lanreotide on the androgen-independent prostate cancer cell line PC3, either sensitive or made resistant to docetaxel (PC3R), as new drugs and new combinations have promising clinical activity in hormone-refra…
  3. 03LabIn vitro (cells)Mechanism

    In docetaxel-resistant PC3R cells, results suggested that lanreotide could inhibit P glycoprotein.

    In plain wordsIn cells resistant to docetaxel, results suggested that lanreotide could inhibit P glycoprotein.

    Peptide
    Lanreotide
    Outcome
    DecreaseP glycoprotein inhibition
    Study

    humann: not reported in source

    PC3 and docetaxel-resistant PC3R prostate cancer cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results suggested that lanreotide could act as a P glycoprotein inhibitor in PC3R cells.
    1 context sentence
    Summary · context
    To evaluate the effects of the association between docetaxel and the somatostatin analogue lanreotide on the androgen-independent prostate cancer cell line PC3, either sensitive or made resistant to docetaxel (PC3R), as new drugs and new combinations have promising clinical activity in hormone-refra…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.